[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607986":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":29,"locations":37,"responsibleParty":173,"collaborators":11,"id":175,"slug":176,"hasResults":177,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":11,"eligibilityCriteria":181,"healthyVolunteers":177,"sex":182,"minAge":183,"maxAge":11,"enrollmentInfo":184,"targetDuration":11,"studyType":187,"phases":188,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":40,"whyStopped":11,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":207},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"BMS-986506: Part 1A","EXPERIMENTAL",null,[13],"Drug: BMS-986506",{"label":15,"type":10,"description":11,"interventionNames":16},"BMS-986506: Part 2A",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"BMS-986506: Part 2B",[13],[21],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","BMS-986506","Specified dose on specified days",[9,15,18],[27],{"name":5,"affiliation":5,"role":28},"STUDY_DIRECTOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":36,"role":32,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[38,56,69,83,97,111,127,143,159],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Dana-Farber Cancer Institute","RECRUITING","Boston","Massachusetts","02215","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-71.05977,42.35843,{"lat":50,"lon":49},[53],{"name":54,"role":32,"phone":55,"phoneExt":11,"email":11},"Stephanie Berg, Site 0006","617-632-4932",{"facility":57,"status":40,"city":58,"state":58,"zip":59,"country":44,"countryCode":45,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Memorial Sloan Kettering Cancer Center","New York","10065",{"type":47,"coordinates":61},[62,63],-74.00597,40.71427,{"lat":63,"lon":62},[66],{"name":67,"role":32,"phone":68,"phoneExt":11,"email":11},"Martin Voss, Site 0029","646-888-4721",{"facility":70,"status":40,"city":71,"state":72,"zip":73,"country":44,"countryCode":45,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Fox Chase Cancer Center","Philadelphia","Pennsylvania","19111",{"type":47,"coordinates":75},[76,77],-75.16362,39.95238,{"lat":77,"lon":76},[80],{"name":81,"role":32,"phone":82,"phoneExt":11,"email":11},"Elizabeth Plimack, Site 0002","215-728-3889",{"facility":84,"status":40,"city":85,"state":86,"zip":87,"country":44,"countryCode":45,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"SCRI Oncology Partners","Nashville","Tennessee","37203",{"type":47,"coordinates":89},[90,91],-86.78444,36.16589,{"lat":91,"lon":90},[94],{"name":95,"role":32,"phone":96,"phoneExt":11,"email":11},"Benjamin Garmezy, Site 0026","713-444-7804",{"facility":98,"status":40,"city":99,"state":100,"zip":101,"country":44,"countryCode":45,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"START San Antonio","San Antonio","Texas","78229",{"type":47,"coordinates":103},[104,105],-98.49363,29.42412,{"lat":105,"lon":104},[108],{"name":109,"role":32,"phone":110,"phoneExt":11,"email":11},"Amita Patnaik, Site 0001","210-593-5250",{"facility":112,"status":40,"city":113,"state":114,"zip":115,"country":116,"countryCode":117,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Arthur J.E. Child Comprehensive Cancer Centre","Calgary","Alberta","T2N 5G2","Canada","CA",{"type":47,"coordinates":119},[120,121],-114.08529,51.05011,{"lat":121,"lon":120},[124],{"name":125,"role":32,"phone":126,"phoneExt":11,"email":11},"Daniel Heng, Site 0021","4035213166",{"facility":128,"status":40,"city":129,"state":130,"zip":131,"country":132,"countryCode":133,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"Gustave Roussy","Villejuif","Val-de-Marne","94800","France","FR",{"type":47,"coordinates":135},[136,137],2.35992,48.7939,{"lat":137,"lon":136},[140],{"name":141,"role":32,"phone":142,"phoneExt":11,"email":11},"Christophe Massard, Site 0008","+33142114211",{"facility":144,"status":40,"city":145,"state":146,"zip":147,"country":148,"countryCode":149,"cosmosGeoPoint":150,"geoPoint":154,"contacts":155},"Hospital Universitario Reina Sofia","Córdoba","Andalusia","14004","Spain","ES",{"type":47,"coordinates":151},[152,153],-4.77275,37.89155,{"lat":153,"lon":152},[156],{"name":157,"role":32,"phone":158,"phoneExt":11,"email":11},"MARIA JOSE MENDEZ VIDAL, Site 0015","+34957011448",{"facility":160,"status":40,"city":161,"state":162,"zip":163,"country":148,"countryCode":149,"cosmosGeoPoint":164,"geoPoint":168,"contacts":169},"Hospital Universitari Vall d'Hebron","Barcelona","Barcelona [Barcelona]","08035",{"type":47,"coordinates":165},[166,167],2.15899,41.38879,{"lat":167,"lon":166},[170],{"name":171,"role":32,"phone":172,"phoneExt":11,"email":11},"Cristina Suarez Rodriguez, Site 0018","349327460004350",{"type":174,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100607986","phase-1-a-first-in-human-study-of-bms-986506-in-participants-with-advanced-clear-cell-renal-cell-carcinoma-ccrcc-100607986",false,"NCT07195682","A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)","A Phase 1\u002F1b Open-label, Multi-center Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)","Inclusion Criteria:\n\n* Participants must have histologically confirmed diagnosis of locally advanced or metastatic ccRCC.\n* For part 1: Participants must have already had at least two different treatment plans in the past, including immunotherapy and a targeted therapy.\n* For part 2: Participants must have had at least one standard treatment plan that included both a PD-1\u002FL1 inhibitor and a VEGF-TKI (either together or one after the other).\n* Participants must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n\nExclusion Criteria:\n\n* Participants with Inability to administer and\u002For tolerate oral medication without chewing, breaking, crushing, or otherwise altering the product dosage form.\n* For Part 2A: Participants who have received more than 3 prior systemic regimens for locally advanced or metastatic ccRCC including prior treatment with HIF2a inhibitors.\n* Participants who have hypoxia as defined by a pulse oximeter reading \\\u003C 92% at rest or requires intermittent or chronic supplemental oxygen.\n* Participants who have received colony-stimulating factors (eg, G-CSF, GM-CSF or recombinant EPO) within 28 days prior to the first dose of study intervention.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL","18 Years",{"count":185,"type":186},125,"ESTIMATED","INTERVENTIONAL",[189],"PHASE1","This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone by participants with ccRCC.",[192],"Renal Cell Carcinoma",[194,195,196,197],"Metastatic clear cell renal cell carcinoma","Advanced clear cell renal cell carcinoma","ccRCC","Kidney cancer","2026-06-08",{"date":200,"type":201},"2026-06-09","ACTUAL",{"date":203,"type":201},"2026-01-15",{"date":205,"type":186},"2031-04-03",{"name":5,"class":6},9]